B. Riley Securities Maintains Buy on Silk Road Medical, Lowers Price Target to $54
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Neil Chatterji has maintained a 'Buy' rating on Silk Road Medical (NASDAQ:SILK) but lowered the price target from $58 to $54.

August 04, 2023 | 11:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Silk Road Medical's price target has been lowered from $58 to $54 by B. Riley Securities, though the 'Buy' rating is maintained.
The lowering of the price target by B. Riley Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price in the short term. However, the maintained 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100